Our studies in cancer biology and pediatric oncology are focused on cellular plasticity, a phenomenon that relates both to the fundamental mechanisms of cancer pathogenesis and to the development of improved rational therapies. Detailed information about our research is available at http://alexkentsis.net.
Alex Kentsis, MD, PhD
Research FocusCancer biologist and pediatric oncologist Alex Kentsis leads research in the functional proteomics and genomic plasticity of refractory childhood cancers.
- MD, Mount Sinai School of Medicine
- PhD, New York University
- Brown FC, Still E, Koche RP, Yim CY, Takao S, Cifani P, Reed C, Gunasekera S, Ficarro SB, Romanienko P, Mark W, McCarthy C, de Stanchina E, Gonen M, Seshan V, Bhola P, O’Donnell C, Spitzer B, Stutzke C, Lavallée VP, Hébert J, Krivstov AV, Melnick A, Paietta EM, Tallman MS, Letai A, Sauvageau G, Pouliot G, Levine R, Marto JA, Armstrong SA, Kentsis A. MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia. Cancer Discovery, 2018 [PMID:29431698]
- Ramaswamy K, Forbes L, Minuesa G, Gindin T, Brown F, Kharas MG, Krivtsov AV, Armstrong SA, Still E, de Stanchina E, Knoechel B, Koche R, Kentsis A. Peptidomimetic blockade of MYB in acute myeloid leukemia. Nature Communications, 2018
- Rita Allen Foundation Scholar Award, Damon Runyon Cancer Research Foundation Clinical Investigator Award (2016), American Society for Clinical Investigation Physician-Scientist Award (2015), American Society of Hematology Scholar Award (2014), Burroughs Wellcome Fund Career Award for Medical Scientists (2013)
- Pediatric Hematology-Oncology Fellowship, Dana-Farber Cancer Institute, Residency in Pediatrics, Boston Children’s Hospital, Harvard Medical School
- MD, PhD, Mount Sinai School of Medicine and New York University
- AB, SM, University of Chicago